



CryoLife, Inc. Stock to be Listed on the Chicago Board Options Exchange

December 20, 2001

ATLANTA, Dec 20, 2001 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts and surgical adhesives, today announced that it has been selected for listing on the Chicago Board Options Exchange (CBOE). Trading is scheduled to begin on or about Thursday, December 20, 2001. The CBOE ticker symbol will be CRY.

CryoLife options will trade on the January expiration cycle with introductory expirations in January, February, April and July. Initial strike prices have been set at 22-1/2, 25 and 30. Susquehanna Investment Group has been named the Designated Primary Market Maker (DPM) in the CryoLife options.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., said, "We are extremely pleased to be included among the more than 1,600 stock options currently listed on the CBOE. This listing provides expanded opportunities for investing in CryoLife, particularly for those whose portfolio activity includes listed options trading.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the SynerGraft vascular graft, the world's first tissue-engineered heart valve and vascular replacements, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: <http://www.cryolife.com>

CONTACT: Roy Vogeltanz, Vice President, Corporate Communications of
CryoLife, Inc., 800-438-8285